2022 forecast: Will biopharma's offices ever go back to 'normal'? Sanofi, Novartis and more chime in

Through much of 2021, it seemed as if COVID-19 vaccines were enabling many countries to gently ease back into normalcy. Those hopes hit a rude awakening late in the year when the omicron variant emerged, and now industry leaders are forced—again—to quickly adapt.